| Sign In to gain access to subscriptions and/or personal tools. |
Kappa Opioid Receptor Screen with the TangoTM β-Arrestin Recruitment Technology and Characterization of Hits with Second-Messenger AssaysSelectScreen Cellular Services, Discovery Assays & Services, Cell Systems Division, Invitrogen Corp., Madison, Wisconsin, chris.doucette{at}invitrogen.com
SelectScreen Cellular Services, Discovery Assays & Services, Cell Systems Division, Invitrogen Corp., Madison, Wisconsin
SelectScreen Cellular Services, Discovery Assays & Services, Cell Systems Division, Invitrogen Corp., Madison, Wisconsin
SelectScreen Cellular Services, Discovery Assays & Services, Cell Systems Division, Invitrogen Corp., Madison, Wisconsin
Roche Nimblegen, Madison, Wisconsin
SelectScreen Cellular Services, Discovery Assays & Services, Cell Systems Division, Invitrogen Corp., Madison, Wisconsin
Assays for high-throughput screening of G-protein-coupled receptors (GPCRs) have typically revolved around receptor binding, guanine nucleotide binding, and second-messenger assays measuring intracellular cAMP and calcium levels. New assay development has been directed toward G-protein-independent signaling pathways, including protein redistribution in response to activated receptors. β-arrestin recruitment to agonist-stimulated GPCRs is the basis for the Transfluor®, PathHunter®, and TangoTM GPCR screening platforms. In the TangoTM GPCR technology, receptor activation results in the recruitment of a TEV protease:β-arrestin fusion protein to the activated receptor where the TEV protease releases the GAL4-VP16 tethered to the target GPCR by a 7—amino acid TEV protease site. The release of the transcription factor results in expression of the β-lactamase (bla) reporter gene. The authors performed a small library screen with a TangoTM cell line expressing the
Key Words: TangoTM • β-arrestin • β-lactamase • opioid • GPCR
Journal of Biomolecular Screening, Vol. 14, No. 4,
381-394 (2009) |
|
||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
opioid receptor and identified a series of compounds with a similar core chemical structure that were selective agonists for the 
opioid receptors. These compounds were validated in additional second-messenger assays, confirming the agonist activity of the identified compounds. These results provide insight into the value of screening compounds in multiple assay technologies to better characterize the compound's potency and efficacy. (Journal of Biomolecular Screening 2009:381-394)